BACKGROUND: Neutrophil gelatinase-associated lipocalin (NGAL) is released by renal tubular cells in response to inflammation and injury. Recent studies have demonstrated that NGAL is up-regulated in cardiomyocytes within the failing myocardium. However, the overall relationship between systemic NGAL levels and myocardial structure and performance has not been established. METHODS AND RESULTS: We measured systemic NGAL levels in 130 subjects with chronic systolic heart failure (HF) and comprehensive echocardiographic evaluation, as well as 69 subjects with acute decompensated systolic HF and hemodynamic evaluation. In the chronic HF cohort, higher plasma NGAL levels were modestly associated with increasing age (r = 0.18; P = .035), higher New York Heart Association functional class (rank sums: P = .022) and impaired renal function (eGFR: r = -0.53; P < .0001; cystatin C: r = 0.60; P < .0001). Plasma NGAL levels were modestly associated with indices of diastolic dysfunction (mitral E/Ea: r = 0.27; P = .002; LAVi: r = 0.25; P = .011; tricuspid E/Ea: r = 0.20; P = .029), but not after adjustment for renal function (P > .10 for all). In Cox proportional hazards analysis, plasma NGAL predicted cardiac death or transplantation after adjustment for age, gender, left ventricular ejection fraction, and mitral E/Ea (hazard ratio 1.68, 95% confidence interval 1.08-2.57; P = .022), but not after adjustment for renal function (P = .83). In the acute HF cohort, we did not observe any relationship between NGAL and hemodynamic indices, but NGAL strongly correlated with renal function. CONCLUSIONS: Systemic NGAL levels are largely determined by underlying impairment of renal rather than myocardial function. Our findings did not support any prognostic significance or relationship between systemic NGAL levels and indices of cardiac structure and function after adjustment for underlying renal function.
BACKGROUND:Neutrophil gelatinase-associated lipocalin (NGAL) is released by renal tubular cells in response to inflammation and injury. Recent studies have demonstrated that NGAL is up-regulated in cardiomyocytes within the failing myocardium. However, the overall relationship between systemic NGAL levels and myocardial structure and performance has not been established. METHODS AND RESULTS: We measured systemic NGAL levels in 130 subjects with chronic systolic heart failure (HF) and comprehensive echocardiographic evaluation, as well as 69 subjects with acute decompensated systolic HF and hemodynamic evaluation. In the chronic HF cohort, higher plasma NGAL levels were modestly associated with increasing age (r = 0.18; P = .035), higher New York Heart Association functional class (rank sums: P = .022) and impaired renal function (eGFR: r = -0.53; P < .0001; cystatin C: r = 0.60; P < .0001). Plasma NGAL levels were modestly associated with indices of diastolic dysfunction (mitral E/Ea: r = 0.27; P = .002; LAVi: r = 0.25; P = .011; tricuspid E/Ea: r = 0.20; P = .029), but not after adjustment for renal function (P > .10 for all). In Cox proportional hazards analysis, plasma NGAL predicted cardiac death or transplantation after adjustment for age, gender, left ventricular ejection fraction, and mitral E/Ea (hazard ratio 1.68, 95% confidence interval 1.08-2.57; P = .022), but not after adjustment for renal function (P = .83). In the acute HF cohort, we did not observe any relationship between NGAL and hemodynamic indices, but NGAL strongly correlated with renal function. CONCLUSIONS: Systemic NGAL levels are largely determined by underlying impairment of renal rather than myocardial function. Our findings did not support any prognostic significance or relationship between systemic NGAL levels and indices of cardiac structure and function after adjustment for underlying renal function.
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: De-xiu Bu; Anne-Louise Hemdahl; Anders Gabrielsen; Jonas Fuxe; Chaoyong Zhu; Per Eriksson; Zhong-qun Yan Journal: Am J Pathol Date: 2006-12 Impact factor: 4.307
Authors: W H Wilson Tang; Wilson Tong; Richard W Troughton; Maureen G Martin; Kevin Shrestha; Allen Borowski; Sue Jasper; Stanley L Hazen; Allan L Klein Journal: J Am Coll Cardiol Date: 2007-06-04 Impact factor: 24.094
Authors: W H Wilson Tang; Kevin Shrestha; Frederick Van Lente; Richard W Troughton; Maureen G Martin; Allen G Borowski; Sue Jasper; Allan L Klein Journal: Am J Cardiol Date: 2008-02-01 Impact factor: 2.778
Authors: F Aigner; H T Maier; H G Schwelberger; E A Wallnöfer; A Amberger; P Obrist; T Berger; T W Mak; M Maglione; R Margreiter; S Schneeberger; J Troppmair Journal: Am J Transplant Date: 2007-04 Impact factor: 8.086
Authors: Thomas L Nickolas; Matthew J O'Rourke; Jun Yang; Meghan E Sise; Pietro A Canetta; Nicholas Barasch; Charles Buchen; Faris Khan; Kiyoshi Mori; James Giglio; Prasad Devarajan; Jonathan Barasch Journal: Ann Intern Med Date: 2008-06-03 Impact factor: 25.391
Authors: W H Wilson Tang; Frederick Van Lente; Kevin Shrestha; Richard W Troughton; Gary S Francis; Wilson Tong; Maureen G Martin; Allen G Borowski; Sue Jasper; Randall C Starling; Allan L Klein Journal: J Card Fail Date: 2008-05-27 Impact factor: 5.712
Authors: Søren Lindberg; Jan S Jensen; Søren Hoffmann; Allan Z Iversen; Sune H Pedersen; Tor Biering-Sørensen; Søren Galatius; Allan Flyvbjerg; Rasmus Mogelvang; Nils E Magnusson Journal: Cardiorenal Med Date: 2016-02-25 Impact factor: 2.041
Authors: Matthias Dupont; Kevin Shrestha; Dhssraj Singh; Adiveh Awad; Cynthia Kovach; Mario Scarcipino; Anjli P Maroo; W H Wilson Tang Journal: Eur J Heart Fail Date: 2012-04-14 Impact factor: 15.534
Authors: Mostafa S K Tawfeek; Doaa M Raafat; Khaled Saad; Naglaa K Idriss; Sherif Sayed; Doaa A Fouad; Amira A El-Houfey Journal: Ther Adv Cardiovasc Dis Date: 2015-11-30